WOONSOCKET, R.I., Aug. 31, 2023 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that President and CEO Karen S. Lynch and Executive Vice President and Chief Financial Officer Shawn Guertin will participate in a fireside chat with investors at the 21st Annual Morgan Stanley Global Healthcare Conference on September 12, 2023, at approximately 8:50 am ET.
An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year.
CVS Health® is the leading health solutions company, broadening access to care for millions of people nationwide. We improve the health of communities across America through our local presence, digital channels and with over 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses, and nurse practitioners. We support individuals with their health – whether that's managing health conditions, staying compliant with their medications or accessing affordable health services in the most convenient ways. Our goal is to create seamless connections across the health care system, simplifying the experience and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Follow @CVSHealth on social media.
| Last Trade: | US$56.83 |
| Daily Change: | 1.06 1.90 |
| Daily Volume: | 11,060,119 |
| Market Cap: | US$71.610B |
November 19, 2024 November 18, 2024 November 06, 2024 November 06, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
